Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 178

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 178
---
 cancer death in the U.S., accounting for about 1 in 5 of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. Overall, the chance that a man will develop lung cancer in his lifetime is about 1 in 16; for a woman, the risk is about 1 in 17. These numbers include both people who smoke and those who don’t smoke. For people who smoke, the risk is much higher, while for those who don’t, the risk is lower.

| ● | Black men are about 12% more                                                                                  
 likely to develop lung cancer than White men. The rate is about 16% lower in Black women than in White women. |

| ● | Black and White women have                                                                                                             
 lower rates than men, but the gap is closing. The lung cancer rate has been dropping among men over the past few decades, but only for 
 about the past decade in women.                                                                                                        |

| ● | Despite their overall risk                                                             
 of lung cancer being higher, Black men are less likely to develop SCLC than White men. |

Statistics on survival in people with lung cancer vary depending on the type of lung cancer, the stage (extent) of the cancer when it is diagnosed, and other factors. 106 5-year relative survival rates for non-small cell lung cancer These numbers are based on people diagnosed with NSCLC between 2012 and 2018.

| SEER stage               |     | 5-year            
 relative survival 
 rate              |    |   |
| Localized                |     |                   | 65 | % |
| Regional                 |     |                   | 37 | % |
| Distant                  |     |                   |  9 | % |
| All SEER stages combined |     |                   | 28 | % |

Our therapeutic approach and development program We designed our clinical development program for CER-1236 to enable our evaluation of its therapeutic utility in treating both hematologic and solid tumors, as the capacity of a single therapeutic construct to provide clinical benefit across this diversity of tumor types would represent a significant advance in cancer immunotherapy. Due to the therapy’s novel mechanism of action, engaging both the innate and the adaptive immune response, and the broad expression profile of PS on a variety of hematologic and solid tumors, we have employed an adaptive Phase 1 trial design to evaluate patient response to CER-1236. As such, the dosing protocol is designed to